Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

132.43 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

52 53 Next >

Erasca Oulicenses Its Mid-Stage Cancer Program To Novartis, Raises $100M Via Equity Offering ↗

December 09, 2022

Via Benzinga

Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib

December 09, 2022

From Erasca, Inc.

Via GlobeNewswire

Novartis' Rare Blood Disorder Therapy Aces Second Late-Stage Trial ↗

December 08, 2022

Via Benzinga

3 Hot Stocks That Could Live Up to Their Lofty Valuations ↗

December 08, 2022

These companies have long runways of growth ahead

Via The Motley Fool

MorphoSys Inks Licensing Agreement With Novartis For Preclinical Cancer Programs ↗

December 07, 2022

Via Benzinga

2 Top Biotech Stocks to Buy Right Now ↗

November 19, 2022

These two rank among the 10 largest pharmaceutical companies on the planet.

Via The Motley Fool

Novartis' Kisqali Prolongs Progression Free Survival Benefit In Metastatic Breast Cancer Versus Chemo ↗

December 07, 2022

Via Benzinga

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Names Experienced Researcher as Advisory Board Member

December 06, 2022

Via Investor Brand Network

Why CSL Ltd Stock Could Be Worth a Look

December 03, 2022

FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment.

Via MarketBeat

First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM

December 02, 2022

By Rachael Green, Benzinga

Via News Direct

First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM

December 02, 2022

On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dosed in its Phase I/II clinical trial of Allocetra. The novel off-the-shelf cell therapy is designed to help break...

Via TheNewswire.com

Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors ↗

December 02, 2022

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.

Via Benzinga

Longwood Healthcare Leaders to Bring Together Several Hundred Top Biotech and Pharmaceutical Leaders on Jan. 5-6, 2023

November 30, 2022

Longwood Fund, an early-stage life science venture firm, will convene several hundred top biotech and pharmaceutical leaders at its Pre-JPM Longwood Healthcare Leaders meeting, hosted virtually via...

Via Newswire.com

10 Health Care Stocks Whale Activity In Today's Session ↗

November 28, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

3 Biotech Stocks Smart Investors Should Be Buying Up Now ↗

November 24, 2022

These three biotech stocks could be among the best ways to play this uncertain market for those looking for long-term growth.

Via InvestorPlace

Novartis' Malaria Treatment Candidate To Move Forward With Phase 3 Development Next Year ↗

November 23, 2022

Via Benzinga

See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch ↗

November 23, 2022

Sales accelerated, again, in the third quarter. Here's what the company and analysts are watching.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

November 22, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

First Patients Dosed in Phase I/II Trial of Enlivex's Off-the-Shelf Cell Therapy Candidate, AllocetraTM ↗

November 22, 2022

On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dose

Via Benzinga

TEVA Stock Alert: What to Know About Teva Pharmaceuticals’ New CEO ↗

November 21, 2022

Teva Pharmaceuticals (TEVA) stock is sliding on Monday after the company announced Richard Francis as its newest president and CEO.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

November 17, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Thoughts For Thursday: Correction Day! ↗

November 17, 2022

The market remains agitated and it looks like it may be a long week from here to Thanksgiving. Yesterday the market remained chiefly in corrective mode, as it was down from the outset.

Via Talk Markets

Novartis Mulls Disposing Its Non-Core Ophthalmology and Respiratory Units ↗

November 16, 2022

Novartis AG (NYSE: NVS) is reportedly weighing divesting non-core assets as it seeks to raise money to invest in cutting-edge medicines, people familiar with the matter said.

Via Benzinga

BioNTech Plans To Set Up Singapore Based mRNA Plant By End Of 2023 ↗

November 14, 2022

Via Benzinga

Should Income Investors Buy This High-Yielding Dividend Stock? ↗

November 13, 2022

Novartis' product portfolio and pipeline bode well for its future.

Via The Motley Fool

Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles ↗

November 10, 2022

Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen.

Via Investor's Business Daily

Drug Repurposing Market to Eyewitness Huge Growth by 2027 : Allergan, Astellas Pharma, Biovista, NuMedii

November 07, 2022

Stay up-to-date with Drug Repurposing Market research offered by AMA. Check how key trends and emerging drivers are shaping this industry growth.

Via SBWire

Leading Data Analytics Company Vizlib Gains ISO 27001 Certification

November 07, 2022

About Vizlib Vizlib has revolutionised the way businesses of every size can get more from their data analytics investment into Qlik. With over 1,000 enterprise and public sector clients across the...

Via PRUnderground

2 Biotech Stocks That Could Make You Richer ↗

November 04, 2022

Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors.

Via The Motley Fool

After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns ↗

October 31, 2022

Via Benzinga

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

52 53 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.